Document

Filter documents

pdf icon

FSRH CEU Statement: Strengthening of Warnings about use of Dianette and other brands of co-cyprindiol (June 2013)

File size: 58kb | Date: 1 June 2013 | Clinical Statements - PDF

Following a recent safety review, a letter has been issued to healthcare professionals from the manufacturers of Dianette® and other cyproterone acetate 2 mg/ ethinylestradiol 35 mcg (co-cyprindiol) products. The review by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) followed concerns about the risk of thrombosis associated with co-cyprindiol. With the agreement of the EMA and Medicines and Healthcare products Regulatory Authority (MHRA), a letter has been issued to raise awareness of the thrombosis risks and the outcome of the review.

pdf icon

FSRH New Product Review: Sayana Press® (June 2013)

File size: 140kb | Date: 1 June 2013 | New Product Reviews - PDF

Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).

pdf icon

FSRH Clinical Standards All Service Standards Jan 2013

File size: 7901kb | Date: 1 January 2013 | Clinical Standards - PDF

These Standards are recommended for organisations providing contraceptive/sexual and reproductive health (SRH) services, including pregnancy planning, pregnancy choices, abortion, prevention and treatment of sexually transmitted infections (STIs), as well as sexual wellbeing and health promotion.

pdf icon

Statement from the FSRH Clinical Standards Committee, the Clinical Effectiveness Committee and the Associate Members’ Working Group on the prescription, administration or supply of Contraceptive Medicines for use outside the terms of their licences Dec 09

File size: 65kb | Date: 1 December 2009 | Clinical Standards - PDF

The above committees have agreed that Clinical Effectiveness Unit Guidance on use of contraceptives is guidance on “common practice” and “current practice” in the use of these medicines and devices. Therefore it is recommended that it may not be necessary for clinicians to document every occasion when a contraceptive preparation is prescribed outside the product licence if such use falls within current guidance issued by the Faculty’s Clinical Effectiveness Unit.

pdf icon

Maintaining Good Medical Practice

File size: 270kb | Date: 1 March 2001 | Clinical Standards - PDF

It has always been a professional responsibility to provide the highest standard of care within the community. However, recently, doctors within the United Kingdom are expected to be able to demonstrate their fitness to practice within clinical governance and revalidation. In line with other professional groups and particularly in line with the Colleges and Faculties with whom we work - the RCOG, the RCGP and the Faculty of Public Health Medicine - it is important for us to demonstrate the elements of maintaining good medical practice within our specialist areas.